Prokidney (PROK) EBIT (2021 - 2026)
Prokidney (PROK) posted quarterly EBIT of -$44.9 million for Q1 2026, down 8.57% year-over-year from -$49.1 million in Q1 2025, and up 0.97% quarter-over-quarter from -$45.4 million in Q4 2025.
Prokidney (PROK) EBIT (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported EBIT for 6 consecutive years, with -$44.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 8.57% year-over-year to -$44.9 million; the TTM figure through Mar 2026 stood at -$168.6 million (up 8.88% YoY), while the FY2025 annual figure was -$165.0 million, up 10.16% from the prior year.
- EBIT rose to -$44.9 million in Q1 2026 per PROK's latest filing, from -$45.4 million in the prior quarter.
- Across five years, EBIT topped out at -$20.7 million in Q2 2022 and bottomed at -$66.5 million in Q1 2022.
- Historically, EBIT has averaged -$41.1 million across 5 years, with a median of -$40.9 million in 2023.
- Annual changes were most pronounced in 2022 — EBIT plunged 1282455.0% — and 2023, when it jumped 38.5%.
- Prokidney's EBIT stood at -$30.2 million in 2022, then climbed by 19.93% to -$24.2 million in 2023, then slumped by 113.02% to -$51.6 million in 2024, then rose by 12.02% to -$45.4 million in 2025, then increased by 0.97% to -$44.9 million in 2026.
- Business Quant data shows PROK's EBIT at -$44.9 million in Q1 2026, -$45.4 million in Q4 2025, and -$38.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Prokidney | 679.95 Mn | 679.95 Mn | - | -48.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.37 Mn |
| Mar 31, 2026 | -44.93 Mn |
| Dec 31, 2025 | -45.37 Mn |
| Sep 30, 2025 | -38.54 Mn |
| Jun 30, 2025 | -39.71 Mn |
| Mar 31, 2025 | -41.39 Mn |
| Dec 31, 2024 | -51.57 Mn |
| Sep 30, 2024 | -48.97 Mn |
| Jun 30, 2024 | -43.06 Mn |
| Mar 31, 2024 | -40.08 Mn |
| Dec 31, 2023 | -24.21 Mn |
| Sep 30, 2023 | -46.62 Mn |
| Jun 30, 2023 | -39.82 Mn |
| Mar 31, 2023 | -40.88 Mn |
| Dec 31, 2022 | -30.24 Mn |
| Sep 30, 2022 | -35.57 Mn |
| Jun 30, 2022 | -20.74 Mn |
| Mar 31, 2022 | -66.46 Mn |
| Dec 31, 2021 | -2.33 Mn |
| Sep 30, 2021 | -17.08 Mn |